These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6180075)

  • 1. Pharmacokinetics of human interferon-beta in monkeys.
    Hilfenhaus J; Damm H; Hofstaetter T; Mauler R; Ronneberger H; Weinmann E
    J Interferon Res; 1981; 1(3):427-36. PubMed ID: 6180075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and antiviral activity of recombinant human interferon-beta ser17 in African green monkeys.
    Chiang J; Gloff CA; Soike KF; Williams G
    J Interferon Res; 1993 Apr; 13(2):111-20. PubMed ID: 8509658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of the kidney in catabolism of human leukocyte interferon.
    Bino T; Edery H; Gertler A; Rosenberg H
    J Gen Virol; 1982 Mar; 59(Pt 1):39-45. PubMed ID: 6175730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptors for human alpha and beta interferon but not for gamma interferon are specified by human chromosome 21.
    Raziuddin A; Sarkar FH; Dutkowski R; Shulman L; Ruddle FH; Gupta SL
    Proc Natl Acad Sci U S A; 1984 Sep; 81(17):5504-8. PubMed ID: 6206498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice.
    Billiau A; Heremans H; Ververken D; van Damme J; Carton H; de Somer P
    Arch Virol; 1981; 68(1):19-25. PubMed ID: 6166278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic comparison of leukocyte and Escherichia coli-derived human interferon type alpha.
    Sarkar FH
    Antiviral Res; 1982 May; 2(1-2):103-6. PubMed ID: 6179467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon crosses blood-cerebrospinal fluid barrier in monkeys.
    Habif DV; Lipton R; Cantell K
    Proc Soc Exp Biol Med; 1975 May; 149(1):287-9. PubMed ID: 1144440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of human beta-interferon-binding sites on human cells.
    Thompson MR; Zhang Z; Fournier A; Tan YH
    J Biol Chem; 1985 Jan; 260(1):563-7. PubMed ID: 2578128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of human recombinant interferon-beta in monkeys and rabbits.
    Gomi K; Morimoto M; Inoue A; Kobayashi H; Deguchi T; Hara T; Nakamizo N
    Gan; 1984 Mar; 75(3):292-300. PubMed ID: 6724230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetics of human fibroblast interferon in rats].
    Satoh Y; Kasama K; Usuki K; Naruse N; Ida N
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):301-6. PubMed ID: 6696463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-induced changes in pharmacokinetics and tumor uptake of 111In-labeled antimelanoma antibody 96.5 in melanoma patients.
    Rosenblum MG; Lamki LM; Murray JL; Carlo DJ; Gutterman JU
    J Natl Cancer Inst; 1988 Apr; 80(3):160-5. PubMed ID: 3346909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity of human beta-interferon for differentiating leukemic HL-60 cells.
    Hamburger AW; White CP; Siebenlist RE; Sedmak JJ; Grossberg SE
    Cancer Res; 1985 Nov; 45(11 Pt 1):5369-73. PubMed ID: 2996760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal administration of human fibroblast interferon in mice, rats, rabbits and dogs.
    Igawa T; Maitani Y; Machida Y; Nagai T
    Chem Pharm Bull (Tokyo); 1990 Feb; 38(2):549-51. PubMed ID: 2337971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on safety problem by skin tests using human beta interferon preparation.
    Muranaka M; Suzuki S
    J Interferon Res; 1984; 4(1):115-22. PubMed ID: 6715910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of interferon-beta activity by fibroblast cells.
    Ramamurthy V; Fleischmann WR
    Antiviral Res; 1986 Aug; 6(5):267-75. PubMed ID: 3094445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Size characteristics of human leucocyte interferon under reducing and non-reducing conditions.
    Braude IA; Lin LS; Stewart WE
    Biochem J; 1981 Mar; 193(3):947-51. PubMed ID: 6171256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responsiveness of human cells trisomic for chromosome 21 to the antiviral action of human immune interferon.
    De Ley M; Billiau A
    Antiviral Res; 1982 May; 2(1-2):97-102. PubMed ID: 6179471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility to exogenously added interferon-beta protein depends on intracellular interferon-beta mRNA level in human glioma cells.
    Osawa H; Mizuno M; Hatano M; Nakahara N; Tsuno T; Kuno T; Endo M; Yoshida J
    Cytokine; 2005 Dec; 32(5):240-5. PubMed ID: 16343929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of interferon alpha-2b and pegylated interferon alpha-2b on menstrual cycles and ovarian hormones in cynomolgus monkeys.
    Enright BP; Compton DR; Collins N; Davis T; McIntyre BS
    Birth Defects Res B Dev Reprod Toxicol; 2009 Feb; 86(1):29-39. PubMed ID: 19243028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of the antiviral and anticellular activities of interferons by mixtures of HuIFN-gamma and HuIFN-alpha or HuIFN-beta.
    Oleszak E; Stewart WE
    J Interferon Res; 1985; 5(2):361-71. PubMed ID: 2989390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.